Aging
Navigate
Research Paper|Volume 11, Issue 19|pp 8433—8462

Brain pyrimidine nucleotide synthesis and Alzheimer disease

Alba Pesini1,2, Eldris Iglesias1,2, M.Pilar Bayona-Bafaluy1,2,3, Nuria Garrido-Pérez1,2,3, Patricia Meade1,2, Paula Gaudó1,2, Irene Jiménez-Salvador1, Pol Andrés-Benito4,5,6, Julio Montoya1,2,3, Isidro Ferrer4,5,6,7,8, Pedro Pesini9, Eduardo Ruiz-Pesini1,2,3,10
  • 1Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain
  • 2Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain
  • 3Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, Spain
  • 4Departamento de Patología y Terapéutica Experimental, Universidad de Barcelona, Hospitalet de Llobregat, Barcelona, Spain
  • 5Centro de Investigaciones Biomédicas en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
  • 6Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
  • 7Servicio de Anatomía Patológica, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
  • 8Instituto de Neurociencias, Universidad de Barcelona, Barcelona, Spain
  • 9Araclon Biotech, Zaragoza, Spain
  • 10Fundación ARAID, Zaragoza, Spain
Received: June 25, 2019Accepted: September 22, 2019Published: September 27, 2019

Copyright © 2019 Pesini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Many patients suffering late-onset Alzheimer disease show a deficit in respiratory complex IV activity. The de novo pyrimidine biosynthesis pathway connects with the mitochondrial respiratory chain upstream from respiratory complex IV. We hypothesized that these patients would have decreased pyrimidine nucleotide levels. Then, different cell processes for which these compounds are essential, such as neuronal membrane generation and maintenance and synapses production, would be compromised. Using a cell model, we show that inhibiting oxidative phosphorylation function reduces neuronal differentiation. Linking these processes to pyrimidine nucleotides, uridine treatment recovers neuronal differentiation. To unmask the importance of these pathways in Alzheimer disease, we firstly confirm the existence of the de novo pyrimidine biosynthesis pathway in adult human brain. Then, we report altered mRNA levels for genes from both de novo pyrimidine biosynthesis and pyrimidine salvage pathways in brain from patients with Alzheimer disease. Thus, uridine supplementation might be used as a therapy for those Alzheimer disease patients with low respiratory complex IV activity.